WEKO3
アイテム
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
http://hdl.handle.net/10069/25919
http://hdl.handle.net/10069/2591985cda046-ab85-400f-b524-97bfa5ba523c
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
JTO5_1404.pdf (267.2 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2011-10-03 | |||||
| タイトル | ||||||
| タイトル | Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Chemotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | EGFR mutation | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Gefitinib | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Non-small cell lung cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Pharmacokinetics | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Nakamura, Yoichi
× Nakamura, Yoichi× Sano, Kazumi× Soda, Hiroshi× Takatani, Hiroshi× Fukuda, Minoru× Nagashima, Seiji× Hayashi, Tomayoshi× Oka, Mikio× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | INTRODUCTION: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Plasma trough levels of gefitinib were measured on days 3 (D3) and 8 (D8) by high-performance liquid chromatography in 44 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status < or =3, age < or = 80 years, and stages IIIB-IV cancer. Epidermal growth factor receptor mutations in 23 patients were analyzed retrospectively. RESULTS: The median plasma gefitinib values were 662 ng/ml on D3 and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587. The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days. Adenocarcinoma, never smoking, and high D8/D3 ratio were associated with better PFS. Multivariate analysis showed that PFS was associated with never smoking and high D8/D3 ratio. Never-smokers with a high D8/D3 ratio showed the best PFS. Overall survival was not associated with the D8/D3 ratio. Epidermal growth factor receptor mutation analysis of 23 patients showed that 15 patients had exon 19 deletion and/or exon 21 point mutation. Median PFS was similar between mutation-positive and mutation-negative individuals in the high D8/D3 group, whereas mutation-negative individuals in the low D8/D3 group showed the worst median PFS. CONCLUSIONS: A high D8/D3 ratio was independently associated with better PFS in patients with NSCLC treated with gefitinib. Our findings suggest that the pharmacokinetics of gefitinib may be involved in its antitumor activity. | |||||
| 書誌情報 |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 巻 5, 号 9, p. 1404-1409, 発行日 2010-09 |
|||||
| 出版者 | ||||||
| 出版者 | the International Association for the Study of Lung Cancer | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 15560864 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA12058455 | |||||
| PubMed番号 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 20651613 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1097/JTO.0b013e3181e59a7b | |||||
| 権利 | ||||||
| 権利情報 | © 2010 by the International Association for the Study of Lung Cancer. | |||||
| 権利 | ||||||
| 権利情報 | This is a non-final version of an article published in final form in Journal of thoracic oncology, 5(9), pp.1404-1409; 2010. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Journal of thoracic oncology, 5(9), pp.1404-1409; 2010 | |||||
